LFMD Q2 2026 - Preliminary Earnings Alert

Event: Quartr Q2 2026 event Retrieved: 2026-08-05T22:06:00Z Comparison mode: maximal Scorecard contract: v1 Source status: release=available | financials=earnings release only | transcript=available (not read for this preliminary stage)

Consensus scorecard

Reported results and guidance

Guidance (full-year revenue and adjusted EBITDA were both revised down; the release states the prior ranges):

• Scorecard recap: revenue of $47.3m missed consensus by 3.8% and GAAP diluted EPS from continuing operations of $(0.16) missed the $(0.1457) estimate by 9.8%.
• Full-year revenue guidance was cut by $14.5m at the midpoint (from $225m to $209m) and full-year adjusted EBITDA guidance was cut by $20.5m at the midpoint (from $14.5m to $(3.0)m), including $2m to $3m of net XYOSTED launch costs.
• The Q4 guide of $60m-$64m of revenue and $3m-$6m of adjusted EBITDA is presented by the company as implying an annualized exit run rate of approximately $250m of revenue and, before XYOSTED launch costs, approximately $22m of annualized adjusted EBITDA.
• CEO Justin Schreiber said adjusted EBITDA "finished below the range we guided to" and that "the near-term impact on profitability was greater than we anticipated."
• CFO Atul Kavthekar attributed the adjusted EBITDA shortfall to elevated customer acquisition costs earlier in the quarter and lower upfront cash collection tied to the company's $39 introductory offer, with monthly performance improving as the quarter progressed.
• The company launched an exclusive telehealth co-marketing collaboration with Halozyme subsidiary Antares Pharma for XYOSTED, a once-weekly subcutaneous testosterone auto-injector.
• Comparisons are on a continuing-operations basis; WorkSimpli was divested on 4 November 2025 and is reported as discontinued operations for all periods presented.

Key bullish aspects

• Gross margin expanded 280 basis points to approximately 89% from 86%, and gross profit was essentially flat at $42.0m despite revenue falling 3.5%, because cost of revenue fell 22.7% to $5.3m.
• Active subscribers rose 20% to 355,671, so the installed base grew even as reported revenue declined — the revenue decline is a pricing and mix effect, not a shrinking customer count.
• Weight Management Program subscribers rose to approximately 108,000 from just under 100,000 at the end of Q1 2026, roughly 8% sequential growth in the largest program.
• The share of new patients choosing multi-month packages rose from approximately 25% year to date before the pricing change to approximately 85% after it, which shifts revenue recognition later but lengthens the contracted relationship.
• Approximately 84% of revenue is recurring subscription revenue, which the CFO describes as the profit engine funding growth.
• The transition away from compounded GLP-1 medications is described as effectively complete, with approximately 95% of new weight management patients now starting on branded therapies — removing a source of regulatory and supply uncertainty.
• Selling and marketing expense fell $1.8m sequentially and other G&A fell approximately $2.2m sequentially, so the planned cost step-down is visible in the quarter.
• G&A fell 5.5% year over year to $13.6m and customer service expense fell 19.1% to $2.6m.
• Interest swung to $0.046m of net income from $(0.661)m of net expense as the company repaid its debt; it ended the quarter with no debt and an undrawn $30m revolving credit facility, which it amended during the quarter.
• Adjusted EBITDA loss of $(3.5)m improved approximately 21% sequentially, and the company guides Q3 to $(1)m-$2m and Q4 to $3m-$6m.
• The XYOSTED collaboration with Halozyme's Antares Pharma is an exclusive arrangement for the only FDA-approved once-weekly subcutaneous testosterone auto-injector, with further partnerships described as advancing toward execution in the second half.

Key bearish aspects

• Both scorecard metrics missed, and the full-year guidance cut is severe: revenue down $14.5m at the midpoint and adjusted EBITDA down $20.5m at the midpoint, from $12m-$17m of profit to $(6.0)m-breakeven.
• Adjusted EBITDA of $(3.5)m fell below the company's own guided range on management's account, and swung $7.4m from $3.9m of profit a year ago.
• The operating loss from continuing operations widened 204% to $(7.1)m and the six-month operating loss widened 355% to $(16.1)m.
• Selling and marketing expense rose 26.6% year over year to $28.0m on 3.5% lower revenue, and is now 59.3% of revenue against 45.2% a year ago; over six months it rose 30.4% to $57.9m.
• Operating cash flow from continuing operations swung to $(6.9)m used from $6.1m provided a year ago, and to $(6.5)m used over six months from $6.4m provided.
• Cash fell 31.7% to $25.1m from $36.8m at 31 December, a $11.6m decline, and the quarter alone consumed $9.3m of cash.
• Total stockholders' equity fell 65.6% to $8.0m from $23.2m at 31 December, against total liabilities of $51.9m; total current liabilities of $46.6m now exceed total current assets of $42.1m.
• Accounts payable rose 28.3% to $18.2m while cash fell, and accounts receivable rose 21.0% to $11.3m on lower revenue.
• Deferred revenue was flat at $10.8m despite the stated shift to multi-month packages, so the longer-duration mix has not yet built a visible deferred-revenue balance.
• The Q3 revenue guide of $48m-$51m brackets a midpoint of $49.5m, barely above the $49.0m reported a year ago, so the second-half revenue recovery the company describes starts from a flat year-over-year base.
• Discontinued operations contributed $1.9m of net income a year ago and nothing this year, so $1.9m of the year-over-year swing in total net loss is the absence of the divested WorkSimpli business.
• Weighted-average shares rose 7.6% to 47.8m, so the per-share loss is struck on a wider base.

Key uncertainties

• The company describes itself as "effectively at the end" of the compounded-to-branded GLP-1 transition, but the release does not quantify how much of the $1.7m revenue decline or the $7.4m adjusted EBITDA swing is attributable to it versus the $39 introductory offer and the pricing change.
• The $39 introductory offer's terms, duration, and the size of the lower upfront cash collection it caused are not disclosed, so the revenue and cash timing effect cannot be sized.
• Full-year guidance implies second-half revenue of $108.1m-$115.1m against $97.4m in the first half and adjusted EBITDA of $2m-$8m against $(8.0)m in the first half; the release does not bridge the swing beyond citing cost savings and a building rebill base.
• The stated exit run rate of approximately $250m of revenue annualizes the Q4 guide, and approximately $22m of annualized adjusted EBITDA is stated before XYOSTED launch costs, so the run-rate figures are not on the same basis as the guided FY 2026 numbers.
• The XYOSTED collaboration's economics are not disclosed beyond $2m-$3m of net launch costs in 2026; no revenue contribution, margin, term, or exclusivity duration is given.
• Adjusted EBITDA is a non-GAAP measure and its reconciliation page was not read for this preliminary, so which items bridge the $(7.1)m operating loss to the $(3.5)m adjusted EBITDA loss is not verified here.
• Weight Management subscribers are given only as approximately 108,000 against just under 100,000 in the prior quarter; no prior-year figure, churn rate, or revenue per subscriber is disclosed, so the 20% total subscriber growth cannot be attributed across programs.
• Women's Health is described as improving with lower customer acquisition costs and new pharmacy products launching in the second half, but no revenue, subscriber, or margin figure is given for it.
• Customer acquisition cost is discussed qualitatively as elevated earlier in the quarter but is never stated as a number in any period.
• With $25.1m of cash, $9.3m of quarterly cash burn, and $8.0m of book equity, the adequacy of liquidity depends on the guided second-half inflection; the release asserts cash will build through year-end but gives no cash-flow guidance.
• The revolving credit facility was amended during the quarter and the amended terms, covenants, and maturity are not described.
• The 4:30 p.m. ET call had just begun at the time of this report and the transcript was not read for this preliminary stage; management's account of the guidance cut, the introductory offer, and the second-half bridge is not assessed here.

Market context

• API Ninjas snapshot: LFMD $3.68 on NASDAQ, volume 1,772,327, quote timestamped 2026-08-05T21:47:35Z, retrieved 2026-08-05T22:04:00Z. The release was published after the U.S. close on 2026-08-05; this is a single quote of unstated session basis captured after the close, not a measured reaction to the release.

Source limitations

• Every actual above comes from the Quartr Q2 2026 earnings release document (3667777). Quartr standardized financials for this event are not yet populated, and the Form 10-Q (3667778) and slide deck (3969497) attached to this event were not read for this preliminary.
• API Ninjas supplied no actual or difference fields for this event, so each beat/miss is calculated locally as Quartr actual minus API Ninjas estimate. The API row carried no fiscal year or quarter, so the exact ticker-and-event-date match path was used.
• Year-over-year percentage changes and the balance-sheet and cash-flow changes are calculated from the release's own columns; where the release prints a percentage itself, the calculated value agrees.
• Adjusted EBITDA is a non-GAAP measure as defined by the company; its reconciliation appears later in the release and was not read for this preliminary.
• The consolidated statements in this release are unaudited.
• Reported EPS is identical on a basic and diluted basis because the company is lossmaking and reports the same weighted-average share count for both.
• All income-statement comparisons are on a continuing-operations basis. WorkSimpli was divested on 4 November 2025 and is presented as discontinued operations for all periods.
• The extracted statement tables interleave three-month and six-month columns; each figure above was assigned by matching it to the corresponding value the company states in its narrative or key-metrics table, and the totals foot.
• The prior-year continuing-operations loss attributable to common stockholders of approximately $3.8m quoted in the release narrative is the $(3.008)m continuing-operations net loss plus $0.777m of preferred dividends; the statement's $(2.396)m line for that period includes discontinued-operations income.
• Subscriber counts, recurring-revenue share, package-mix percentages, the branded-GLP-1 share, and the liquidity description are quoted from the release narrative.

Source links

• Quartr Q2 2026 earnings release
• Quartr release highlights page
• Quartr release management commentary page
• Quartr release guidance and key metrics page
• Quartr release balance sheet page
• Quartr release statements of operations page
• Quartr release statements of cash flows page